Clinical study results

In mCSPC, ERLEADA® gave certain men a chance to live longer.

In men with prostate cancer that HAS SPREAD to other parts of the body and STILL responds to a medical or surgical treatment that lowers testosterone

ERLEADA® + ADT* was compared with placebo† + ADT in a clinical study of 1052 men with metastatic castration-sensitive prostate cancer (mCSPC).

In this study, patients received either ERLEADA® at a dose of 240 mg once daily or placebo. All patients in the study received ADT.*

In this clinical study, ERLEADA® +ADT reduced the risk of death by 33% vs men taking placebo + ADT

ERLEADA® gave certain men more time without their cancer progressing

In this clinical study, ERLEADA® +ADT reduced the risk of prostate cancer progressing by 52% vs men taking placebo + ADT

The clinical study for men with mCSPC also evaluated this additional measure:

ERLEADA® gave certain men more time without starting chemotherapy

In this clinical study, ERLEADA® + ADT reduced the risk of beginning chemotherapy by 61% vs men taking placebo + ADT

*Androgen deprivation therapy includes medical or surgical treatment that lowers testosterone.

Pronounced "pluh-see-bow": a pill that looks like "real" medicine but contains nothing to affect health.

Progression was defined as the length of time patients lived without their disease spreading further as measured by imaging studies or dying.

In nmCRPC, ERLEADA® helped delay the spread of prostate cancer.

In men with prostate cancer that HAS NOT SPREAD to other parts of the body and NO LONGER responds to a medical or surgical treatment that lowers testosterone

ERLEADA® + ADT* was compared with placebo + ADT in a clinical study of 1207 men with non-metastatic castration-resistant prostate cancer (nmCRPC).

In this study, patients received either ERLEADA® at a dose of 240 mg once daily or placebo. All patients in the study received ADT.*

In this clinical study, ERLEADA® + ADT delayed the spread of cancer to other parts of the body or death by 2 years (24.3 months) compared with placebo + ADT

MEDIAN MONTHS: Median number of months living without metastasis.

 

The clinical study for men with nmCRPC also evaluated overall survival, progression-free survival, and time to chemotherapy.

ERLEADA® (apalutamide) nmCRPC clinical study results showing improved overall survival

Progression-Free Survival

Length of time patients lived without their prostate cancer spreading to local or distant parts of the body or death.

MEDIAN MONTHS

40.5
WITH
ERLEADA®
+ ADT

VS

14.7
WITH
PLACEBO
+ ADT

ERLEADA® (apalutamide) nmCRPC clinical study results showing reduced time to chemotherapy

*Androgen deprivation therapy includes medical or surgical treatment that lowers testosterone.

Pronounced “pluh-see-bow”: a pill that looks like “real” medicine but contains nothing to affect health.

Median means that for 50% of the patients, living without metastasis was longer than 40.5 months, and for 50% of the patients, it was shorter than 40.5 months.

Helpful Information and Resources

Patient and doctor during office visit discussing ERLEADA® (apalutamide)

Doctor Discussion Guide

Contains questions to help start a conversation with your doctor.

Download

Boxing coach with prostate cancer from ERLEADA® (apalutamide) commercial ringside

ERLEADA® Patient Brochure

Contains important information about mCSPC, nmCRPC, and ERLEADA®.

Download